AI assistant
Wave Life Sciences Ltd. — Director's Dealing 2022
Feb 19, 2022
31900_dirs_2022-02-18_4afd381a-6d53-47b5-8758-f08743bef1e4.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Wave Life Sciences Ltd. (WVE)
CIK: 0001631574
Period of Report: 2022-02-16
Reporting Person: Panzara Michael A. (See Remarks)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2022-02-16 | Ordinary Shares | S | 10603 | $2.31 | Disposed | 75817 | Direct |
Footnotes
F1: On February 16, 2022, the reporting person sold 10,603 ordinary shares solely to cover taxes associated with the vesting of restricted share units ("RSUs") on February 15, 2022. These sales were made pursuant to a provision in the reporting person's RSU agreement that requires automatic sales of shares to cover tax withholding obligations.
F2: The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $2.31 to $2.38 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.